Trial Profile
A Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Registrational; Therapeutic Use
- Sponsors NPS Pharmaceuticals
- 15 Nov 2021 Results of Post- Hoc analysis from NCT00081458 and NCT00798967, evaluating patient liver chemistries, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
- 18 May 2014 New trial record